Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: June 9, 2025
Reporting Period: Fiscal Year 2026 Outlook Update
Context: This filing serves as a Regulation FD disclosure to update investors and analysts on the company's growth strategies, operational performance, and financial outlook following scheduled meetings.
Key Financial Metrics
The filing focuses on forward-looking guidance rather than historical financial results for the current period. Specific historical revenue, profit, cash flow, or debt figures are not provided in this document.
- Adjusted Earnings per Diluted Share (FY 2026): Updated range of $36.90 to $37.70.
- Effective Tax Rate (FY 2026): Reaffirmed range of 17% to 19%.
- Effective Tax Rate (H1 FY 2026): Anticipated range of 17% to 20% (higher in Q1 than Q2).
- Effective Tax Rate (H2 FY 2026): Anticipated range of 16% to 19%.
Material Changes Versus Prior Period
McKesson has increased its full-year Adjusted Earnings per Diluted Share guidance compared to the previous outlook provided on May 8, 2025.
- Prior Guidance (May 8, 2025): $36.75 to $37.55 per share.
- New Guidance (June 9, 2025): $36.90 to $37.70 per share.
- Other Guidance: All other guidance provided on May 8, 2025, remains reaffirmed.
Guidance, Outlook, and Risks
Management Commentary and Non-GAAP Measures
Management utilizes Adjusted Earnings per Diluted Share as a primary Non-GAAP measure. The company does not provide forward-looking GAAP guidance due to the inability to reasonably forecast specific items such as LIFO inventory adjustments, litigation contingencies, restructuring charges, and impairments without unreasonable effort.
Material Risks and Contingencies
The filing outlines significant risks that could cause actual results to differ materially from projections, including:
- Legal and Regulatory: Costly disputes regarding the distribution of controlled substances (opioids), changing healthcare laws, and tax legislation challenges.
- Operational: Cybersecurity incidents, data breaches, and information system failures.
- Financial: Impairment charges to goodwill and intangibles, customer payment defaults, and credit market disruptions.
- Strategic: Risks related to acquisitions, divestitures, and the integration of strategic transactions.
- External Factors: Supply chain disruptions, healthcare reform, geopolitical factors, and climate change impacts.
Investor Verification Checklist
- Verify the reconciliation of the new Adjusted EPS guidance ($36.90–$37.70) against the most recent GAAP results to understand the magnitude of non-GAAP adjustments.
- Review the May 8, 2025, Form 8-K and earnings call materials to confirm the specific details of the "other guidance" that was reaffirmed.
- Assess the potential impact of the anticipated higher Q1 tax rate (17%–20%) on near-term cash flows.
- Monitor ongoing litigation developments related to opioid distribution and their potential effect on future earnings and insurance coverage.
- Confirm the status of any pending acquisitions or divestitures mentioned in prior filings that could influence the FY 2026 outlook.